Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access of its StemVacs Product for American Cancer Patients

Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA
under President Donald Trump’s 
Right to Try Law

Read More

TSOI Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene

Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline

Read More

Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board

Company to Initiate Investigational Cardiovascular Study with Dr. Azimi and NanoStilbene

Read More

Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment Centers

Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene

Read More

Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board

Dr. James Veltmeyer to Assist Company in Expansion of Clinical Applications of Pterostilbene Based Therapeutics

Read More

StemVacs is a platform for antigen-nonspecific immune modulatory treatment that can be utilized as a monotherapy or as a combination with antigen-specific modalities such as peptide or protein based vaccines.

Nutraceutical Products – TSI has been producing very high quality nutraceuticals. Its flagship product, Projuvenol®, is a Patented (No. 9,682,047) proprietary mixture containing pterostilbene – one of the most potent antioxidants known.